Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-EBOV Phase 1 in Healthy Africans in China
NCT02401373Phase 1Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad5-EBOV in Ebola virus disease (EVD) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Safety and side-effect profile at 28 days, Tolerability at 28 days and 1 more. Started Mar 2015; status: completed.
02
Drugs
Ad5-EBOV
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02401373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401373.